Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Approved to Start China Trials of Bi-Specific PD-1 Candidate

publication date: Feb 7, 2019

Suzhou Innovent Biologics was granted NMPA approval to start trials of a PD-1 bi-specific drug in patients with hematological and advanced solid tumors. In December, Innovent's lead PD-1 candidate, Tyvyt® (sintilimab), was approved for marketing in China (see story). The IND approval announced today is for IBI318, which targets the programmed cell death protein 1 (PD-1) and an undisclosed tumor-associated antigen (TAA). Innovent expects the bi-specific mechanism will make the PD-1 mechanism more effective in solid tumors. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.